FXIa
53 programs · 51 companies
Programs
53
Companies
51
Active Trials
33
Targeting FXIa
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | DLBCL | |
| RHH-682 | Roche | Phase 2 | OCDRB | |
| RHH-7975 | Roche | Phase 3 | FTDRA | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | Heart FailureSCLC | |
| Pexazasiran | Sanofi | Preclinical | ASRA | |
| Rimaosocimab | Amgen | Preclinical | FLDravet | |
| GIL-9142 | Gilead Sciences | Phase 1 | EoE | |
| BII-5449 | Biogen | Phase 3 | Prostate Ca | |
| BGN-8936 | BeiGene | Phase 1/2 | AngelmanSMA | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | HCC | |
| Terainavolisib | Immunocore | Preclinical | ALLCF | |
| EDI-3618 | Editas | NDA/BLA | Endometrial CaADHD | |
| Semarapivir | Bluebird Bio | Phase 2 | ThymomaET | |
| SGM-3567 | Sangamo | Phase 2/3 | Asthma | |
| Polasotorasib | Aslan Pharma | NDA/BLA | SCLCCeliac | |
| HOR-3601 | Horizon (Amgen) | Phase 1/2 | CLLThymoma | |
| IPS-8044 | Century | Preclinical | Wet AMDNB | |
| Zanurapivir | Abivax | NDA/BLA | PBCCKD | |
| Talarelsin | Candel Therapeutics | NDA/BLA | Pancreatic Ca | |
| GLY-5612 | GlycoMimetics | Phase 3 | MS | |
| Rimabrutinib | Molecular Templates | Preclinical | MigraineFSGS | |
| Ribozanubrutinib | Theratechnologies | Phase 2/3 | HCC | |
| BTA-1886 | Bioxcel Therapeutics | Phase 1 | ThymomaHuntington's | |
| ALE-8045 | Alexion (AZN) | Phase 1 | MGMDD | |
| LAE-3866 | Laekna | Phase 1/2 | FLEwing Sarcoma | |
| Lirazumab | Transcenta | Phase 2 | ASRB | |
| 000-7991 | Yuhan Corp | Phase 1 | RCCGA | |
| CAR-3300 | Caris Life Sci | Approved | Bladder CaFL | |
| AJA-3524 | Ajax Ther | Phase 1/2 | FTDPancreatic Ca | |
| GEN-3979 | Generate Bio | Phase 1 | IPF | |
| Lisocilimab | Catalyst Bio (Vertex) | Phase 2/3 | Heart FailureLGS | |
| GEN-IIT-381 | Genethon | Phase 2 | CF | |
| Cevirasimod | Arrowhead Pharma | Preclinical | Ovarian Ca | |
| TUR-4928 | Turnstone Bio | Phase 2/3 | HNSCC | |
| Bemarapivir | Nippon Shinyaku | Phase 2/3 | CSU | |
| Zenosertib | Avidity Bio | Phase 2/3 | CTCLFabry | |
| Mavulemzoparlimab | Clinigen | Phase 3 | FSGSADHD | |
| MRE-2348 | Mereo BioPharma | Preclinical | Heart FailurePompe | |
| MRK-3890 | Merck KGaA | Phase 2 | GBM | |
| Sematuximab | Affimed | Phase 2/3 | MyelofibrosisPsA | |
| RCE-4101 | Avita Medical | Phase 1/2 | CeliacGIST | |
| BER-3725 | BerGenBio | Phase 3 | WMAS | |
| FER-3003 | Ferring Pharma | Phase 1/2 | WilmsMeso | |
| NTC-6338 | NTC Pharma | Approved | ASCeliac | |
| Gelinaritide | Cadila Healthcare | Phase 1/2 | Cervical CaEwing Sarcoma | |
| MAN-3628 | Mankind Pharma | Phase 1 | TTR AmyloidosisCLL | |
| NAT-IIT-452 | Natl Cancer Ctr Singapore | Phase 3 | GBM | |
| TAT-IIT-251 | Tata Memorial Hosp | NDA/BLA | EoE | |
| TAT-IIT-689 | Tata Memorial Hosp | Phase 1 | Huntington's | |
| PET-IIT-689 | Peter MacCallum | NDA/BLA | Pancreatic Ca | |
| RAB-IIT-137 | Rabin Medical Center | Phase 1/2 | NMOSD | |
| WST-3903 | West Pharma | Preclinical | GAADPKD | |
| ZHE-6042 | Zhejiang Jiuzi | Phase 2 | PBCAS |